Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.

Graf WD, Nagel SK, Epstein LG, Miller G, Nass R, Larriviere D.

Neurology. 2013 Mar 26;80(13):1251-60. doi: 10.1212/WNL.0b013e318289703b. Epub 2013 Mar 13. Review.

PMID:
23486879
2.

Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications.

Rothman SM.

Neurology. 2013 Oct 22;81(17):1558. doi: 10.1212/01.wnl.0000437277.02794.3a. No abstract available.

PMID:
24145884
4.

Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee.

Larriviere D, Williams MA, Rizzo M, Bonnie RJ; AAN Ethics, Law and Humanities Committee.

Neurology. 2009 Oct 27;73(17):1406-12. doi: 10.1212/WNL.0b013e3181beecfe. Epub 2009 Sep 23.

5.

Addressing the problem of ADHD medication as neuroenhancements.

Graf WD, Miller G, Nagel SK.

Expert Rev Neurother. 2014 May;14(5):569-81. doi: 10.1586/14737175.2014.908707. Epub 2014 Apr 17. Review.

PMID:
24738763
6.

Cognitive enhancement in children and adolescents: is it in their best interests?

Gaucher N, Payot A, Racine E.

Acta Paediatr. 2013 Dec;102(12):1118-24. doi: 10.1111/apa.12409. Epub 2013 Sep 21.

PMID:
24033708
7.

ADHD and stimulant drug treatment: what can the children teach us?

Erler A.

J Med Ethics. 2013 Jun;39(6):357-8. doi: 10.1136/medethics-2013-101562. No abstract available.

PMID:
23689793
8.

[The origin of informed consent].

Mallardi V.

Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27. Italian.

PMID:
16602332
9.

Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder.

Brinkman WB, Sherman SN, Zmitrovich AR, Visscher MO, Crosby LE, Phelan KJ, Donovan EF.

Pediatrics. 2009 Aug;124(2):580-9. doi: 10.1542/peds.2008-2569. Epub 2009 Jul 27.

PMID:
19651580
10.

Globalization and cognitive enhancement: emerging social and ethical challenges for ADHD clinicians.

Singh I, Filipe AM, Bard I, Bergey M, Baker L.

Curr Psychiatry Rep. 2013 Sep;15(9):385. doi: 10.1007/s11920-013-0385-0. Review.

PMID:
23933975
12.
13.

Family pediatrics: report of the Task Force on the Family.

Schor EL; American Academy of Pediatrics Task Force on the Family.

Pediatrics. 2003 Jun;111(6 Pt 2):1541-71.

PMID:
12777595
14.

Might stimulant drugs support moral agency in ADHD children?

Hyman SE.

J Med Ethics. 2013 Jun;39(6):369-70; discussion 372-3. doi: 10.1136/medethics-2012-100846. Epub 2012 Sep 21.

15.

The use, misuse and diversion of prescription stimulants among middle and high school students.

McCabe SE, Teter CJ, Boyd CJ.

Subst Use Misuse. 2004 Jun;39(7):1095-116.

PMID:
15387205
16.

Medication management of stimulants in pediatric practice settings: a national perspective.

Hoagwood K, Jensen PS, Feil M, Vitiello B, Bhatara VS.

J Dev Behav Pediatr. 2000 Oct;21(5):322-31.

PMID:
11064959
17.
18.

Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people.

Boot BP, Partridge B, Hall W.

Neurocase. 2012 Jun;18(3):181-4. doi: 10.1080/13554794.2011.588174. Epub 2011 Oct 18.

PMID:
22007842
19.

Pediatrician and family physician prescription of selective serotonin reuptake inhibitors.

Rushton JL, Clark SJ, Freed GL.

Pediatrics. 2000 Jun;105(6):E82.

PMID:
10835095
20.

Supplemental Content

Support Center